Philip Yearian, DPM
Podiatrist · Lakewood, WANPI 1255307807
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (52.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Summit Surgical Corp. at 52.1% of the total. Reporting peaked in 2021 at $2,884 and has fallen 88.8% since, to $324 in 2025.
Across 44 payments — averaging $104.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Summit Surgical Corp.$2K
- Paragon 28, Inc.$1K
- Bioventus LLC$168
- Integra Lifesciences Corporation$148
- Zimmer Biomet$111
- Stryker$98
- plus $604 from 20 others
What the payments were for
- Travel & lodging$79517%
- Food & beverage$1,41531%
- Education$2,40052%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Summit Surgical Corp. | 2 | $2,400 |
| Paragon 28, Inc. | 7 | $1,081 |
| Bioventus LLC | 2 | $168 |
| Integra Lifesciences Corporation | 1 | $148 |
| Zimmer Biomet | 1 | $111 |
| Stryker(2 entities) | 4 | $98 |
| Polynovo North America LLC | 2 | $89 |
| Orthofix Medical, Inc. | 4 | $76 |
| Anika Therapeutics, Inc. | 1 | $56 |
| Pfizer | 2 | $46 |
| Stimlabs LLC | 1 | $38 |
| Pacira Therapeutics, Inc. | 2 | $30 |
| Merck | 2 | $30 |
| Next Science LLC | 1 | $29 |
| Ossio Inc | 1 | $26 |
| Organogenesis Inc. | 1 | $23 |
| Vertex | 1 | $22 |
| Heron Therapeutics, Inc. | 1 | $20 |
| Zimvie Inc. | 1 | $20 |
| Osiris Therapeutics Inc. | 1 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Smith+Nephew | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Convatec Inc. | 1 | $15 |
| Zyla Life Sciences, Inc. | 1 | $11 |
| Fusion Orthopedics USA, LLC | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,610 in reported general payments places this provider in the 85th percentile of 134 podiatrist providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 79 | $593 |
| Terbinafine Hcl | 78 | $458 |
| Cephalexin | 39 | $252 |
| Fluconazole | 28 | $245 |
| Gabapentin | 17 | $112 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Lakewood
- Gavin SmithLakewood$4K
- Byron HutchinsonBurien$903K
- Michael DujelaCentralia$99K
- Huy DangCentralia$63K
- Michael FrazierFederal Way$27K
- Ryan StoneBurien$15K
- Alvin NganSeattle$13K
- Tony KimWenatchee$11K
- Anthony MollicaBellevue$11K
- Todd ChappellTacoma$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.